Clot-Busting drug before transfer may boost stroke recovery
NCT ID NCT07203625
First seen Oct 31, 2025 · Last updated Jun 10, 2026 · Updated 33 times
Summary
This study tests whether giving a clot-busting drug (tenecteplase) before transferring patients with a severe stroke in the back of the brain (basilar artery occlusion) to a specialized hospital can improve recovery. About 316 adults who had a stroke 4.5 to 24 hours earlier will receive the drug or a placebo before a procedure to remove the clot. The goal is to see if more people regain independence at 90 days.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Xuanwu Hospital, Capital Medical University
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.